Beranda › Sindrom Mielodisplastik › Colorado › Denver
Uji klinis Sindrom Mielodisplastik di Denver, CO
4 studi untuk Sindrom Mielodisplastik mencari peserta di lokasi sekitar Denver (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Menerima pesertaFase 3
- Presbyterian / St. Luke'S Medical Center, Denver
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Menerima pesertaFase 1/2
- Colorado Blood Cancer Institute, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Denver
Uji klinis Sindrom Mielodisplastik di kota lain
- Houston, TX43 studi
- Baldwin Park, CA26 studi
- New York City, NY21 studi
- Seattle, WA21 studi
- Washington, DC20 studi
- Tampa, FL19 studi
- Boston, MA19 studi
- Miami, FL17 studi
- Durham, NC14 studi
- Columbus, OH14 studi
- St. Louis, MO13 studi
- Atlanta, GA13 studi
Studi lain di Denver
- Kanker Metastatik29 studi
- Kanker Payudara29 studi
- Kanker Paru Non-Sel Kecil27 studi
- Mieloma Multipel27 studi
- Kanker Kolorektal23 studi
- Melanoma19 studi
- Kanker Prostat19 studi
- Kanker (semua jenis)18 studi
- Kanker Ovarium16 studi
- Kanker Paru16 studi
- Kanker Endometrium15 studi
- Limfoma Non-Hodgkin14 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.